Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.74 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418775 | 0.88 | KDM4E (1.00) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL3059795 | 0.86 | KDM4E (0.76) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL20836643 | 0.84 | KDM4E (0.60) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL298290 | 0.82 | KDM4E (1.00) | KDM4EALDH1A1GAARAB9AMAPT | |
| SCHEMBL290132 | 0.81 | KDM4E (1.00) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL288846 | 0.80 | KDM4E (0.84) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL290222 | 0.79 | KDM4E (0.64) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL4167344 | 0.78 | ALDH1A1 (0.67) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL289704 | 0.77 | KDM4E (0.79) | KDM4EALDH1A1GAARAB9AKMT2A | |
| SCHEMBL10091957 | 0.76 | KDM4E (0.61) | KDM4EALDH1A1GAARAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1751149-B1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LAB (US) | 2012-06-06 | — | — | EP | disclosed |
| EP-2427447-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | Pike Pharma GmbH (CH) | 2012-03-14 | — | — | EP | disclosed |
| EP-2308873-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | Abbott Laboratories (US) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010128163-A2 | SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION | PIKE PHARMA GMBH (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-1751149-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7098222-B2 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBVIE INC. | 2005-12-08 | — | — | US | disclosed |
| WO-2005113551-A1 | BICYCLIC-SUBSTITUTED AMINES HAVING CYCLIC-SUBSTITUTED MONOCYCLIC SUBSTITUENTS | ABBOTT LABORATORIES (US) | 2005-12-01 | — | — | WO | disclosed |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | ABBOTT LABORATORIES | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272728-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | KDM4E 1783/4885ALDH1A1 2284/4885GAA 3058/4885 |
| US-20050256118-A1 | Bicyclic-substituted amines having cyclic-substituted monocyclic substituents | HRH3, HRH4, HRH2 | KDM4E 1783/4885ALDH1A1 2284/4885GAA 3058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.